Let us discuss how some of its key drugs performed in the quarter So far this year, Amgen’s stock has risen 8.8% against the industry‘s 1.4% decline. In general medicine, Repatha is Amgen’s ...

In cardiometabolic, Amgen takes out at the expense of Repatha, which fights Praluent and a newer RNA molecule from Novartis— inclisiran. The market here is huge, and the demand is enormous.

Q1 2025. Management View. CEO Robert Bradway emphasized a strong start to 2025, highlighting 9% year-over-year revenue growth and 14% vol ...

We're impressed with strong growth for cancer drug Blincyto (52% growth), asthma drug Tezspire (65%), cholesterol drug Repatha (27%), and osteoporosis drug Evenity (29%). Despite Amgen's growing ...

Fourteen products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieved double-digit volume growth in the quarter. Let us discuss how some of its key drugs performed in the quarter So ...